A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors (INVOKE)
NCT 06789172 Brief Summary The purpose of this study is to investigate…
Read more arrow_forwardNCT 06789172 Brief Summary The purpose of this study is to investigate…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12623000307606 Brief Summary This study is investigating a new cancer treatment…
Read more arrow_forwardACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 06929663 Brief Summary This is an first-in-human, Phase I clinical study…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forward